Daniel Guidot

My research focuses on two main aims: effective care and equitable care in interstitial lung disease (ILD). My methods focus on using existing data collected on patients during routine care and employing advanced biostatistical or other computational methods to gain insights into causal pathways of disease and mediators of inequities in outcomes.

For effective care, my work seeks to understand disease-modifying factors whether they are negative factors that drive ILD progression such as toxic exposures or whether they are beneficial factors like pharmaceuticals or lung transplantation. I use Duke, VA, and national data to study why and how ILD progresses as well as when it is most effective to employ interventions. This work is currently supported by funding from the Mario Family Foundation Grant, the Duke Clinical Research Institute's Executive Director's Pathways Grant, the Duke Institute for Health Innovation Automation to Enhance Healthcare Operational Efficiency Grant, and the pulmonary T32 PROSPER Grant.

For equitable care, my work seeks to understand and define disparities and inequities in health care in any form, including disparities by patient race, by patient geography, by patient age, or by any other factor that can make a population vulnerable to inequities in outcomes. I use the same methods and data sources to both quantify the disparities but also study mediators of those disparities to inform health care interventions that can reduce them. This work is currently supported by funding from the Mario Family Foundation Grant and the pulmonary T32 PROSPER Grant.